201 related articles for article (PubMed ID: 24156027)
1. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
Chen JL; Appelbaum DE; Kocherginsky M; Cowey CL; Rathmell WK; McDermott DF; Stadler WM
Cancer Med; 2013 Aug; 2(4):545-52. PubMed ID: 24156027
[TBL] [Abstract][Full Text] [Related]
2. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
3. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
[TBL] [Abstract][Full Text] [Related]
4.
van Es SC; Brouwers AH; Mahesh SVK; Leliveld-Kors AM; de Jong IJ; Lub-de Hooge MN; de Vries EGE; Gietema JA; Oosting SF
J Nucl Med; 2017 Jun; 58(6):905-910. PubMed ID: 28082434
[TBL] [Abstract][Full Text] [Related]
5. The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.
Kakizoe M; Yao M; Tateishi U; Minamimoto R; Ueno D; Namura K; Makiyama K; Hayashi N; Sano F; Kishida T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Taguri M; Morita S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2014 Jun; 14():390. PubMed ID: 24885730
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
[TBL] [Abstract][Full Text] [Related]
7. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
Kayani I; Avril N; Bomanji J; Chowdhury S; Rockall A; Sahdev A; Nathan P; Wilson P; Shamash J; Sharpe K; Lim L; Dickson J; Ell P; Reynolds A; Powles T
Clin Cancer Res; 2011 Sep; 17(18):6021-8. PubMed ID: 21742806
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
9. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.
Stein A; Bellmunt J; Escudier B; Kim D; Stergiopoulos SG; Mietlowski W; Motzer RJ;
Eur Urol; 2013 Dec; 64(6):994-1002. PubMed ID: 23219086
[TBL] [Abstract][Full Text] [Related]
10. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
11. mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response.
Lamuraglia M; Raslan S; Elaidi R; Oudard S; Escudier B; Slimane K; Penna RR; Wagner M; Lucidarme O
Eur Radiol; 2016 Jan; 26(1):278-85. PubMed ID: 25953002
[TBL] [Abstract][Full Text] [Related]
12. Early assessment with
Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
[TBL] [Abstract][Full Text] [Related]
13. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
14. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
Minamimoto R; Barkhodari A; Harshman L; Srinivas S; Quon A
PLoS One; 2016; 11(4):e0153321. PubMed ID: 27123976
[TBL] [Abstract][Full Text] [Related]
16. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
[TBL] [Abstract][Full Text] [Related]
18. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
Ueno D; Yao M; Tateishi U; Minamimoto R; Makiyama K; Hayashi N; Sano F; Murakami T; Kishida T; Miura T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2012 May; 12():162. PubMed ID: 22551397
[TBL] [Abstract][Full Text] [Related]
19. A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma.
Kim DW; Oh DY; Shin SH; Kang JH; Cho BC; Chung JS; Kim H; Park KU; Kwon JH; Han JY; Kim MJ; Bang YJ
BMC Cancer; 2014 Nov; 14():795. PubMed ID: 25362970
[TBL] [Abstract][Full Text] [Related]
20. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Ma WW; Jacene H; Song D; Vilardell F; Messersmith WA; Laheru D; Wahl R; Endres C; Jimeno A; Pomper MG; Hidalgo M
J Clin Oncol; 2009 Jun; 27(16):2697-704. PubMed ID: 19380450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
